UBS Group’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-2,500
Closed -$375K – 11362
2026
Q2
$375K Buy
+2,500
New +$272K ﹤0.01% 6418
2025
Q3
– Sell
-30,200
Closed -$1.57M – 10528
2025
Q2
$1.57M Buy
+30,200
New +$1.35M ﹤0.01% 5049
2024
Q2
– Sell
-40,000
Closed -$825K – 9719
2024
Q1
$825K Buy
+40,000
New +$857K ﹤0.01% 4754

Other funds holding GH

UBS Group's GH Position: Q3 2026 in Review

UBS Group increased its Guardant Health (GH) stake by 33% in Q3 2026, buying an estimated $46.3M and bringing the position to 1,149,570 shares worth $205M. The position accounts for 0.03% of the portfolio, ranked #642.

UBS Group first reported a position in GH in Q4 2018 and has held it in 32 quarters since. 676 funds tracked by Wall St. Rank hold GH as of Q3 2026.

  • UBS Group held 1,149,570 shares of Guardant Health worth $205M as of Q3 2026.
  • UBS Group bought 283,524 Guardant Health shares in Q3 2026, an estimated $46.3M.
  • Guardant Health made up 0.03% of UBS Group's portfolio in Q3 2026, its #642 holding.
  • UBS Group first reported a position in Guardant Health in Q4 2018 and has held it in 32 quarters since.
  • 676 funds tracked by Wall St. Rank held Guardant Health as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.